PPARay Agonists

This is a new class of compounds that is being tried in clinical studies for simultaneous treatment for hyperglycaemia and hypertriglyceridaemia. They act by stimulating the PPARg nuclear receptors (similar action to the glitazones) and the PPARa nuclear receptors (similar action to the fibrates). Several compounds have reached phase III clinical trials (muraglitazar, tesaglitazar, MK0767, etc.) but none has yet been approved for clinical use. Concerns regarding their cardiovascular and renal safety, as well as regarding carcinogenicity issues in animals, have been raised.

0 0

Post a comment